Cybin Inc. is upgraded to Buy, driven by recent regulatory and clinical tailwinds that favor its lead candidate, HLP003.

Psychedelic stocks surged in premarket trading on Monday after President Donald Trump signed an executive order on Saturday ...

Looking at Cybin Inc.'s ( NASDAQ:HELP ) insider transactions over the last year, we can see that insiders were ...

- Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with 28 patents granted and 158 patents pending - - Creates strong synergies by combining ...

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by ...

Visit a quote page and your recently viewed tickers will be displayed here. Eric So is the founder of Globalive Technology Partners, Inc. (founded in 2017), Cybin, Inc. (founded in 2016), and Cybin ...

Positive Clinical Progress: Cybin Inc. has reported significant advancements in its clinical programs, notably achieving a primary efficacy endpoint in its Phase 2 study of CYB003 for treating Major ...

- Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data ...

Psychedelics company Cybin Inc. CYBN announced an overnight marketed public offering of its units and confirmed its set pricing on an aggregate 24,264,706 Cybin units, at $0.34 each, for aggregate ...